Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
M.D. Anderson Cancer Center
Bayer
Boehringer Ingelheim
Seagen Inc.
National Institutes of Health Clinical Center (CC)
Compass Therapeutics
Pliant Therapeutics, Inc.
Nested Therapeutics, Inc
Compass Therapeutics
Novartis
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
M.D. Anderson Cancer Center
Genentech, Inc.
Boehringer Ingelheim
Shanghai Henlius Biotech
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
The Methodist Hospital Research Institute
OncoC4, Inc.
Pfizer
M.D. Anderson Cancer Center
USWM, LLC (dba US WorldMeds)
KaliVir Immunotherapeutics
Pfizer
Iovance Biotherapeutics, Inc.
Biocon Limited
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Bio-Thera Solutions
Pfizer
Bayer
Institut Claudius Regaud
iOnctura
Genentech, Inc.
Sotio Biotech Inc.
Pfizer
Pfizer
Dana-Farber Cancer Institute